0001144204-19-034598.txt : 20190712
0001144204-19-034598.hdr.sgml : 20190712
20190712165148
ACCESSION NUMBER: 0001144204-19-034598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190710
FILED AS OF DATE: 20190712
DATE AS OF CHANGE: 20190712
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexxon Holdings Ltd.
CENTRAL INDEX KEY: 0001636684
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38667
FILM NUMBER: 19953406
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
BUSINESS PHONE: 972-4-636404
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexcel Pharma Technologies Ltd.
CENTRAL INDEX KEY: 0001720007
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38667
FILM NUMBER: 19953407
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
BUSINESS PHONE: 97246364040
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oren Dan
CENTRAL INDEX KEY: 0001636701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38667
FILM NUMBER: 19953408
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Urovant Sciences Ltd.
CENTRAL INDEX KEY: 0001740547
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 5281 CALIFORNIA AVENUE
STREET 2: SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
BUSINESS PHONE: 949-226-6029
MAIL ADDRESS:
STREET 1: 5281 CALIFORNIA AVENUE
STREET 2: SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
4
1
tv525130_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-07-10
1
0001740547
Urovant Sciences Ltd.
UROV
0001636684
Dexxon Holdings Ltd.
1 DEXCEL STREET
OR AKIVA
L3
30600000
ISRAEL
0
0
0
1
See remarks
0001720007
Dexcel Pharma Technologies Ltd.
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
0
1
See remarks
0001636701
Oren Dan
1 DEXCEL STREET
OR AKIVA
L3
30600000
ISRAEL
0
0
0
1
See remarks
This Form 4 relates to the common shares (the "Common Shares") of Urovant Sciences Ltd. (the "Issuer"). On July 10, 2019, the board of directors of Roivant Sciences Ltd. ("Roivant") adopted changes to Roivant's internal governance concerning the disposition of the Common Shares and other matters relating to oversight of Roivant's business and governance. Following the amendments adopted on July 10, 2019, disposition of the Common Shares requires either the approval of a majority of Roivant's board, including (i) at least two directors meeting certain independence criteria (each, an "Independent Director" and, collectively, the "Independent Directors") or, (ii) if there is only one Independent Director, that sole Independent Director. Andrew Lo and Patrick Machado are currently Independent Directors of Roivant. However, the vote of a majority of Roivant's shareholders holding 5% or more of Roivant's shares (other than Vivek Ramaswamy) may override certain decisions of Roivant's board of directors, including with respect to dispositions of Common Shares. As a result of these changes, the Reporting Persons and other major shareholders of Roivant no longer have the individual right to veto dispositive decisions of Roivant's board of directors regarding disposition of the Common Shares, and so have ceased to have beneficial ownership of the Common Shares directly owned by Roivant. Roivant's ownership of the Issuer's Common Shares remains unchanged and this filing is not being made as a result of the purchase or sale of Common Shares of the Issuer by any party, including the Reporting Persons.
/s/ Dexxon Holdings Ltd. by Dan Oren, Director
2019-07-12
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, President & CEO
2019-07-12
/s/ Dan Oren
2019-07-12